FDA Advisory Panel Backs Pfizer Vaccine for Kids Ages 5 to 11

Headline Roundup October 27th, 2021

On Wednesday, an independent Food and Drug Administration (FDA) advisory panel recommended the Pfizer-BioNTech vaccine for children ages 5 to 11.  The children would receive one-third the amount of active ingredient compared to adults, and they would receive a second dose 21 days or more after the first shot.

The vote is a key step towards providing the vaccine for young kids, but the FDA will need to formally authorize it, and the Centers for Disease Control and Prevention (CDC) will need to weigh in before shots can be given. Both the FDA and the CDC are expected meet to discuss the recommendation sometime during the next week.

From the Center
coronavirus, coronavirus vaccine, FDA, Pfizer, children

A panel of independent advisers to the Food and Drug Administration is recommending that the agency issue an emergency use authorization for the Pfizer-BioNTech vaccine in children ages 5 to 11 years old. The vote was 17 in favor and one abstention.

The FDA panel accepted Pfizer's data indicating the vaccine is safe and 90.7% effective in preventing COVID-19 infections in this age group.

The agency typically goes along with the advice of its expert panels, though it isn't bound to do so. It will issue a decision within the next several...

Read full story
From the Left

Pfizer's request to roll out COVID-19 vaccines for Americans as young as 5 years old cleared a key regulatory hurdle Tuesday, after a panel of the Food and Drug Administration's outside vaccine advisers voted by a majority to back Pfizer's request. 

The vote is a crucial step towards vaccinations for younger children, but not the final word. If the FDA decides to formally authorize the vaccine, the Centers for Disease Control and Prevention must also weigh in with its own recommendations before shots can be rolled out. 

"I do think we need it as...

Read full story
From the Right

Advisers to the Food and Drug Administration recommended on Wednesday that children ages 5 to 11 receive the Pfizer-BioNTech vaccine.

The FDA's advisory committee announced the decision after a study found that the benefits for children who receive inoculation far outweigh the potential risks of cardiac arrest symptoms, according to the Washington Post.

The panel voted unanimously to support the Pfizer-BioNTech vaccine for children. Next, a group of advisers from the Centers for Disease Control and Prevention is expected to have a conference on Nov. 2 regarding the use of the vaccine for children, after...

Read full story
Some content from this outlet may be limited or behind a paywall.